Loading...
01/11 03:09
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call highlights several concerns: unclear management responses to critical questions, ongoing clinical hold, and lack of precise financial guidance. Despite some positive aspects like reduced net loss and strategic financing options, the uncertainty surrounding safety events and potential regulatory challenges outweigh the positives. Given the company's market cap, the stock price is likely to experience a negative reaction in the short term.
Cash, cash equivalents and marketable securities $669.9 million as of September 30, 2025, compared to $861.7 million as of December 31, 2024. The decrease is attributed to operational expenses and investments in the clinical pipeline.
Collaboration revenue $13.8 million during the third quarter of 2025 compared to $9.1 million during the prior year quarter. The $4.7 million increase was mainly driven by cost reimbursements related to the collaboration with Regeneron Pharmaceuticals.
R&D expenses $94.7 million during the third quarter of 2025 compared to $123.4 million during the prior year quarter. The $28.7 million decrease was primarily driven by reductions in employee-related expenses, stock-based compensation, research materials, and contracted services, offset by an increase in the advancement of lead programs.
Stock-based compensation expense (R&D) $12.2 million for the third quarter of 2025.
G&A expenses $30.5 million during the third quarter of 2025, unchanged from the prior year quarter. Stock-based compensation expense included within G&A was $7.4 million for the third quarter of 2025.
Net loss $101.3 million for the third quarter of 2025, down from $135.7 million for the prior year quarter. The reduction is attributed to lower R&D expenses and operational efficiencies.
nex-z: Phase III clinical trials (MAGNITUDE and MAGNITUDE-2) for ATTR amyloidosis are paused due to a patient safety incident. The FDA has placed a clinical hold on these trials. Despite challenges, the company remains optimistic about nex-z's potential to address unmet needs in ATTR amyloidosis.
lonvo-z: Phase III clinical trial (HAELO) for hereditary angioedema (HAE) completed enrollment in less than 9 months. Top-line data expected by mid-2026, with a potential U.S. commercial launch in the first half of 2027. The product aims to redefine HAE treatment by eliminating attacks with a single dose.
Financial Position: Cash, cash equivalents, and marketable securities totaled $669.9 million as of September 30, 2025, down from $861.7 million at the end of 2024. The company raised $115 million through its ATM facility and implemented restructuring initiatives to extend its cash runway into mid-2027.
Collaboration Revenue: Collaboration revenue increased to $13.8 million in Q3 2025 from $9.1 million in Q3 2024, driven by cost reimbursements from Regeneron Pharmaceuticals.
R&D and G&A Expenses: R&D expenses decreased to $94.7 million in Q3 2025 from $123.4 million in Q3 2024, while G&A expenses remained flat at $30.5 million. The company expects a year-over-year decline in GAAP operating expenses of at least 10%.
Restructuring Initiatives: Implemented in early 2025 to reduce costs and extend cash runway, supporting the company's focus on its lead programs and future capabilities.
Clinical Hold on MAGNITUDE and MAGNITUDE-2 Trials: The FDA placed a clinical hold on the MAGNITUDE and MAGNITUDE-2 trials following a patient's death and liver-related adverse events. This has paused patient dosing and screening, delaying the development timeline for nex-z and impacting milestone guidance.
Safety Concerns with nex-z: Grade 4 liver transaminase elevations have been reported in less than 1% of patients in the MAGNITUDE trial, raising concerns about the safety profile of nex-z. Additional monitoring and risk mitigation strategies are being considered.
Regulatory Uncertainty: The company is awaiting the FDA's formal clinical hold letter and must engage with global regulatory authorities to address concerns and requirements, creating uncertainty around the resumption of trials and future approvals.
Financial Sustainability: The company reported a significant decrease in cash reserves from $861.7 million to $669.9 million over nine months, despite raising $115 million. While the cash runway extends to mid-2027, financial pressures could intensify if delays persist.
Dependence on lonvo-z Commercialization: The company is heavily reliant on the successful commercialization of lonvo-z for HAE, with plans for a U.S. launch in 2027. Any setbacks in this program could further strain financial and operational resources.
nex-z Phase III clinical trials (MAGNITUDE and MAGNITUDE-2): The company is working with global regulatory authorities to develop a plan to resume enrollment in the trials after a clinical hold due to a patient safety incident. The company remains committed to the potential of nex-z to address unmet needs in ATTR amyloidosis and plans to provide updates once a plan is finalized.
lonvo-z Phase III clinical trial (HAELO): Enrollment was completed in September 2025, and the company plans to share top-line data by mid-2026. A BLA submission to the FDA is anticipated in the second half of 2026, with a commercial launch in the U.S. expected in the first half of 2027. The company believes lonvo-z could redefine the HAE treatment landscape by eliminating attacks and the need for other medications for most patients with a single dose.
Financial outlook: The company has extended its cash runway into mid-2027, supported by restructuring initiatives and funds raised from its ATM facility. This timeline aligns with the anticipated commercial launch of lonvo-z in the U.S.
The selected topic was not discussed during the call.
The earnings call highlights several concerns: unclear management responses to critical questions, ongoing clinical hold, and lack of precise financial guidance. Despite some positive aspects like reduced net loss and strategic financing options, the uncertainty surrounding safety events and potential regulatory challenges outweigh the positives. Given the company's market cap, the stock price is likely to experience a negative reaction in the short term.
The earnings call summary and Q&A session reveal strong financial health, optimistic guidance, and significant progress in clinical trials. Enrollment is ahead of projections, and the company is on track with its BLA filing timeline. The positive market reaction is bolstered by the announcement of new drugs entering the market and strong patient and physician interest. Despite some management responses being unclear, the overall sentiment is positive, suggesting a stock price increase of 2% to 8% over the next two weeks.
The earnings call summary presents a mixed outlook: while there are cost reductions and strategic pipeline prioritizations, there are also declines in collaboration revenue and workforce reductions that could impact operations. The Q&A section reveals some management avoidance on specifics, potentially raising concerns. Despite this, the company's financial health appears stable with a substantial cash reserve, and there is optimism about future product launches. Given the market cap, the stock price reaction is likely to remain within a neutral range, reflecting both positive and negative factors.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
